← Issue №13/ week of Sep 27, 2026/Endoscopy

High-resolution Manometry Catheter Insertion During Sedated Endoscopy; A Viable Option When Standard Intubation Fails.

From GI Signals issue №13: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Endoscopy retrospective · n=88 · Sep 22, 2026 · J Neurogastro Motil · IF 3.4

High-resolution Manometry Catheter Insertion During Sedated Endoscopy; A Viable Option When Standard Intubation Fails.

New evidenceendoscopy qualitysedation
Clinical takeawayConsider sedated endoscopic insertion of HRM catheters for patients who cannot tolerate routine unsedated intubation or when standard insertion fails, as it enables protocol completion without adverse events. Ensure appropriate pre-sedation assessment (ASA class, Mallampati, BMI, OSA risk, fasting status) and monitoring.
What it foundSedated endoscopic insertion (EI) of HRM catheters achieved 89.8% intubation success and 88.6% protocol completion, comparable to routine unsedated insertion (RI) (80.7% success, 72.7% completion; P = 0.008).
ContextThis study confirms that EI is a viable alternative to RI for HRM catheter placement in patients who cannot undergo standard testing, but requires proper sedation protocols and patient selection.
Measured against the standard of care· ESGE/ESGENA 2026 (PMID 42480549); ASGE 2026 remimazolam clinical practice update (PMID 42848339); ESGE/ESGENA/ESA NAAP 2015; ASGE 2018; ASA 2018 moderate sedation; multisociety GLP-1 perioperative guidance 2024

Decision at stakethe use of sedated endoscopy for high-resolution manometry catheter placement when standard intubation fails

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Match the pre-sedation assessment, the drug regimen and the monitoring to the patient's risk and the complexity of the procedure. Before every sedated procedure, check ASA class, Mallampati score, BMI, OSA risk and fasting status. Propofol and midazolam-with-opiate are both strongly recommended. Using propofol as first line depends on national legislation and staffing, not on proof that it works better. Remimazolam is an ultra-short-acting benzodiazepine, FDA-approved for procedural sedation in July 2020, with fast onset, short duration, organ-independent metabolism and flumazenil reversibility. It is an accepted alternative to midazolam and propofol. Consider it especially in high-risk patients: the elderly and those with cardiorespiratory comorbidity. ESGE/ESGENA 2026 says this, and the ASGE 2026 clinical practice update now covers it, the first ASGE document to address remimazolam (the ASGE 2018 sedation guideline covered only midazolam and propofol). Whoever gives the sedation must be able to rescue a patient one level deeper than intended. Involve an anesthesiology specialist for emergency endoscopy with raised aspiration risk, hemodynamic instability or significant comorbidities. Do the same electively for ASA >=3, Mallampati >=3, severe OSA or an expected difficult airway. Manage GLP-1 receptor agonists case by case rather than stopping them by default. Discharge the patient against a scoring system, with an adult accompanying them and 24-hour restrictions.

ESGE/ESGENA 2026 (PMID 42480549); ASGE 2026 remimazolam clinical practice update (PMID 42848339); ESGE/ESGENA/ESA NAAP 2015; ASGE 2018; ASA 2018 moderate sedation; multisociety GLP-1 perioperative guidance 2024 · reviewed 2026-10-11 ↗
Endersby J … Sweis R · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink
← Read the whole of issue №13 Every paper GI Signals surfaces gets a page like this one. All issues